The DOI matches its Crossref record; 268 of the 268 references it cites were found in a registry or an index.
The making of bispecific antibodies
Open accessAbstract
During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibodies, molecules with an IgG structure, and large complex molecules composed of different antigen-binding moieties often combined with dimerization modules. The application of sophisticated molecular design and genetic engineering has solved many of the technical problems associated with the formation of bispecific antibodies such as stability, solubility and other parameters that confer drug properties. These parameters may be summarized under the term 'developability'. In addition, different 'target product profiles', i.e., desired features of the bispecific antibody to be generated, mandates the need for access to a diverse panel of formats. These may vary in size, arrangement, valencies, flexibility and geometry of their binding modules, as well as in their distribution and pharmacokinetic properties. There is not 'one best format' for generating bispecific antibodies, and no single format is suitable for all, or even most of, the desired applications. Instead, the bispecific formats collectively serve as a valuable source of diversity that can be applied to the development of therapeutics for various indications. Here, a comprehensive overview of the different bispecific antibody formats is provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–268 of 268
Walters, B. T., Jensen, P. F., Larraillet, V., Lin, K., Patapoff, T. W., Schlothauer, T., Rand, K. D., & Zhang, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.691568 · Cited by 45
Wu, S.-C., Chen, Y.-J., Wang, H.-C., Chou, M.-Y., Chang, T., Yuan, S. F., Chen, C.-Y., Hou, M., Hsu, J. T.-A., & Wang, Y. (2015) · Theranostics · doi:10.7150/thno.13069 · Cited by 45
Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
Davé, E., Adams, R., Zaccheo, O., Carrington, B., Compson, J. E., Dugdale, S., Airey, M., Malcolm, S., Hailu, H., Wild, G., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1210747 · Cited by 44
A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action
Brack, S., Attinger-Toller, I., Schade, B., Mourlane, F., Klupsch, K., Woods, R., Hachemi, H., von der Bey, U., Koenig-Friedrich, S., Bertschinger, J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0046-t · Cited by 43
Castoldi, R., Jucknischke, U., Pradel, L. P., Arnold, E., Klein, C., Scheiblich, S., Niederfellner, G. J., & Sustmann, C. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzs048 · Cited by 43
Natsume, A., Wakitani, M., Yamane‐Ohnuki, N., Shoji-Hosaka, E., Niwa, R., Uchida, K., Satoh, M., & Shitara, K. (2006) · The Journal of Biochemistry · doi:10.1093/jb/mvj157 · Cited by 42
Di-diabody: a novel tetravalent bispecific antibody molecule by design
Lu, D., Jimenez, X., Zhang, H., Atkins, A., Brennan, L., Balderes, P. J., Böhlen, P., Witte, L., & Zhu, Z. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00251-5 · Cited by 42
The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen
Correia, I., Sung, J. J., Burton, R. E., Jakob, C. G., Carragher, B. O., Ghayur, T., & Radziejewski, C. H. (2013) · mAbs · doi:10.4161/mabs.24258 · Cited by 42
LUZ-Y, a Novel Platform for the Mammalian Cell Production of Full-length IgG-bispecific Antibodies
Wranik, B. J., Christensen, E., Schaefer, G., Jackman, J. K., Vendel, A. C., & Eaton, D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.397869 · Cited by 40
DiGiammarino, E. L., Harlan, J. E., Walter, K. A., Ladror, U. S., Edalji, R. P., Hutchins, C. W., Lake, M. R., Greischar, A. J., Liu, J., Ghayur, T., et al. (2011) · mAbs · doi:10.4161/mabs.3.5.16326 · Cited by 40
Stamova, S., Cartellieri, M., Feldmann, A., Arndt, C., Koristka, S., Bartsch, H., Bippes, C. C., Wehner, R., Schmitz, M., Bonin, M. V., et al. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.09.019 · Cited by 40
Dong, J., Sereno, A., Snyder, W. B., Miller, B., Tamraz, S., Doern, A., Favis, M., Wu, X., Tran, H., Langley, E. J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.184317 · Cited by 39
A new class of bispecific antibodies to redirect T cells for cancer immunotherapy
Rossi, D. L., Rossi, E. A., Cardillo, T. M., Goldenberg, D. M., & Chang, C. (2013) · mAbs · doi:10.4161/mabs.27385 · Cited by 39
Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments
Lu, D., Jimenez, X., Zhang, H., Böhlen, P., Witte, L., & Zhu, Z. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(02)00148-5 · Cited by 39
An efficient route to the production of an IgG-like bispecific antibody
Zuo, Z., Jimenez, X., Witte, L., & Zhu, Z. (2000) · Protein Engineering Design and Selection · doi:10.1093/protein/13.5.361 · Cited by 39
LC-MS characterization and purity assessment of a prototype bispecific antibody
Woods, R. J., Xie, M. H., von Kreudenstein, T. S., Ng, G., & Dixit, S. B. (2013) · mAbs · doi:10.4161/mabs.25488 · Cited by 38
Gupta, P., Goldenberg, D. M., Rossi, E. A., & Chang, C. (2010) · Blood · doi:10.1182/blood-2010-03-276857 · Cited by 38
Golay, J., Choblet, S., Iwaszkiewicz, J., Cérutti, P., Ozil, A., Loisel, S., Pugnière, M., Ubiali, G., Zoete, V., Michielin, O. A., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501592 · Cited by 37
Atwell, J. L., Pearce, L. A., Lah, M., GRUEN, L. C., Kortt, A. A., & Hudson, P. J. (1996) · Molecular Immunology · doi:10.1016/s0161-5890(96)00097-1 · Cited by 36
Igawa, T., Tsunoda, H., Kikuchi, Y., Yoshida, M., Tanaka, M., Koga, A., Sekimori, Y., Orita, T., Aso, Y., Hattori, K., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq034 · Cited by 36
Poovassery, J. S., Kang, J. C., Kim, D., Ober, R. J., & Ward, E. S. (2014) · International Journal of Cancer · doi:10.1002/ijc.29378 · Cited by 35
Schäfer, W. M., Völger, H. R., Lorenz, S. H., Imhof-Jung, S., Regula, J. T., Klein, C., & Mølhøj, M. (2015) · mAbs · doi:10.1080/19420862.2015.1111498 · Cited by 35
Production and characterization of bispecific single-chain antibody fragments
Jonge, J. D., Brissinck, J., Heirman, C., Demanet, C. J., Léo, O., Moser, M., & Thielemans, K. (1995) · Molecular Immunology · doi:10.1016/0161-5890(95)00089-5 · Cited by 34
Ren‐Heidenreich, L., Davol, P. A., KOUTTAB, N. M., Elfenbein, G. J., & Lum, L. G. (2004) · Cancer · doi:10.1002/cncr.20060 · Cited by 34
Xie, Z., Guo, N., Yu, M., Hu, M., & Shen, B. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.11.005 · Cited by 33
Fennell, B. J., McDonnell, B., Tam, A. S. P., Chang, L., Steven, J., Broadbent, I. D., Gao, H., Kieras, E., Alley, J., Luxenberg, D. P., et al. (2013) · mAbs · doi:10.4161/mabs.26201 · Cited by 33
Yazaki, P. J., Lee, B., Channappa, D., Cheung, C.-W., Crow, D. M., Chea, J., Poku, E. K., Li, L., Andersen, J. T., Sandlie, I., et al. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzs096 · Cited by 33
Functional assessment of antibody oxidation by native mass spectrometry
Haberger, M., Heidenreich, A.-K., Schlothauer, T., Hook, M., Gassner, J., Bomans, K., Yegres, M., Zwick, A., Zimmermann, B., Wegele, H., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1052199 · Cited by 32
Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
Kang, J. C., Poovassery, J. S., Bansal, P., You, S., Manjarrés, I. M., Ober, R. J., & Ward, E. S. (2013) · mAbs · doi:10.4161/mabs.27658 · Cited by 32
Harmsen, M. M., Fijten, H., Dekker, A., & Eblé, P. L. (2008) · Veterinary Microbiology · doi:10.1016/j.vetmic.2008.04.030 · Cited by 32
Ahmed, M., Cheng, M. H., Cheung, I. Y., & Cheung, N. V. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.989776 · Cited by 31
DeNardo, D. G., Xiong, C., Shi, X.-B., et al. (2001) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/10849780152752128 · Cited by 30
Lee, C. V., Koenig, P. S., & Fuh, G. (2014) · mAbs · doi:10.4161/mabs.28483 · Cited by 30
Wu, X., Sereno, A., Huang, F., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007826 · Cited by 28
Korn, T., Müller, R., & Kontermann, R. E. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200403000-00003 · Cited by 28
Self-citationLi, A., Xing, J., Li, L., Zhou, C., Dong, B., He, P., Li, Q., & Wang, Z. (2016) · AMB Express · doi:10.1186/s13568-016-0201-4 · Cited by 26
Castoldi, R., Schanzer, J., Panke, C., Jucknischke, U., Neubert, N. J., Croasdale, R., Scheuer, W., Auer, J., Klein, C., Niederfellner, G. J., et al. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw037 · Cited by 26
Schoonjans, R., Willems, A. V., Schoonooghe, S., Leœn, J., Grooten, J., & Mertens, N. (2001) · Biomolecular Engineering · doi:10.1016/s1389-0344(01)00066-1 · Cited by 25
Craig, R., Summa, C. M., Corti, M., & Pincus, S. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046778 · Cited by 25
Rossi, E. A., Chang, C., Cardillo, T. M., & Goldenberg, D. M. (2012) · Bioconjugate Chemistry · doi:10.1021/bc300488f · Cited by 24
Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule
Kelton, C., Wesolowski, J. S., Soloviev, M., Schweickhardt, R. L., Fischer, D., Kurosawa, E., McKenna, S. D., & Gross, A. W. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.005 · Cited by 24
Mayer, K., Baumann, A.-L., Grote, M., Seeber, S., Kettenberger, H., Breuer, S., Killian, T., Schäfer, W., & Brinkmann, U. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126037 · Cited by 24
Self-citationHe, Y. Z., Hendriks, D., van Ginkel, R., Samplonius, D. F., Bremer, E., & Helfrich, W. (2015) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2015.11.009 · Cited by 24
François, B., Chastre, J. E., Eggiman, P., Laterre, P., Torres, A., García, M. S., Esser, M. T., Bishop, B., Bonten, M. J. M., Goosens, H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw245 · Cited by 24
Clinical perspectives of bispecific antibodies in cancer
GAST, G. C. D., van de Winkel, J. G. J., & Bast, B. J. E. G. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050412 · Cited by 22
Rational Design of Antirheumatic Prodrugs Specific for Sites of Inflammation
Onuoha, S. C., Ferrari, M., Sblattero, D., & Pitzalis, C. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39232 · Cited by 21
Gu, J., Yang, J., Chang, Q., Lu, X., Wang, J., Chen, M., Ghayur, T., & Gu, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097292 · Cited by 20
Chen, C., Zhang, Y., Zhang, Y., Li, J., Tsao, S. W., & Zhang, M.-Y. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0558 · Cited by 20
Schuurman, J., & Parren, P. W. H. I. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.04.001 · Cited by 20
Gu, J., Yang, J., Chang, Q., Liu, Z., Ghayur, T., & Gu, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124135 · Cited by 19
Complex and defined biostructures with the dock-and-lock method
Rossi, E. A., Goldenberg, D. M., & Chang, C. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.06.001 · Cited by 19
ErbB3 Inhibitory Surrobodies Inhibit Tumor Cell Proliferation In Vitro and In Vivo
Foreman, P. K., Gore, M., Kobel, P. A., Xu, L., Yee, H., Hannum, C. H., Ho, H., Wang, S. M., Tran, H. V., Horowitz, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0068 · Cited by 19
Choi, H., Kim, Y., Choi, D.-K., & Kim, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145349 · Cited by 19
Generation of Bispecific Antibodies by Chemical Conjugation
Ellerman, D. A., & Scheer, J. M. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_3 · Cited by 18
Shen, Y., Zeng, L., Novosyadlyy, R., Forest, A., Zhu, A., Korytko, A. I., Zhang, H., Eastman, S. W., Topper, M. B., Hindi, S., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1055442 · Cited by 18
Kumagai, I. (2011) · Oncology Reports · doi:10.3892/or.2011.1382 · Cited by 18
Bispecific Antibody Derivatives Based on Full-Length IgG Formats
Grote, M., Haas, A. K., Klein, C., Schäfer, W. M., & Brinkmann, U. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-931-0_16 · Cited by 16
Self-citationTetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma
Lu, C.-Y., Chen, G. J., Tai, P., Yang, Y., Hsu, Y.-S., Chang, M., & Hsu, C.-L. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.03.124 · Cited by 16
Symmetry of Fv architecture is conducive to grafting a second antibody binding site in the Fv region
Keck, P. C., & Huston, J. S. (1996) · Biophysical Journal · doi:10.1016/s0006-3495(96)79398-0 · Cited by 15
Milutinovic, S., Kashyap, A. K., Yanagi, T., Wimer, C. D., Zhou, S., O’Neil, R. E., Kurtzman, A. L., Faynboym, A., Xu, L., Hannum, C. H., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0400 · Cited by 15
Kim, H., Park, S., Lee, H. K., & Chung, J. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.83 · Cited by 14
Yoon, S., Kim, Y., Kang, S. H., Kim, S.-K., Lee, H. K., Kim, H., Chung, J., & Kim, I.-H. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1548-4 · Cited by 12
Zeng, J., Liu, R., Wang, J., & Fang, Y. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1949-7 · Cited by 11
Fang, M. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.10.032 · Cited by 11
Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody
Wang, L., He, Y., Zhang, G., Ma, J., Liu, C., He, W. Z., Wang, W., Han, H., Boruah, B. M., & Gao, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075589 · Cited by 11
Alternative Triggering Molecules and Single Chain Bispecific Antibodies
Segal, D. M., Sconocchia, G., TITUS, J. A., Jost, C. R., & KURUCZ, I. (1995) · Journal of Hematotherapy · doi:10.1089/scd.1.1995.4.377 · Cited by 11
Zettlitz, K. A., Seitter, J., Müller, D., & Kontermann, R. E. (2010) · Molecular Biotechnology · doi:10.1007/s12033-010-9298-x · Cited by 10
Self-citationSong, J.-Z., Wang, X., Lei, C., Piao, J., Yin, C., Zhang, Z., Lin, Q., & Hualiang, H. (2006) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20060060 · Cited by 4
Cited by
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
T cell-engaging therapies — BiTEs and beyond
Goebeler, M.-E., & Bargou, R. C. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0347-5 · Cited by 644
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
“Dimerization of two nanobodies or scFvs can also be achieved by genetic fusion to natural or synthetic dimerization domains (56).”
Background
Metadata
- Authors
- Brinkmann, U., & Kontermann, R. E.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2017-01-10
- Volume
- 9
- Issue
- 2
- Pages
- 182-212
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2571138221
- Cited by
- 923
- References
- 268
- FWCI
- 58.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.